Literature DB >> 16575498

Pharmacokinetic consequences of active drug efflux at the blood-brain barrier.

Stina Syvänen1, Rujia Xie, Selma Sahin, Margareta Hammarlund-Udenaes.   

Abstract

PURPOSE: The objective of this simulation study was to investigate how the nature, location, and capacity of the efflux processes in relation to the permeability properties influence brain concentrations.
METHODS: Reduced brain concentrations can be due to either influx hindrance, a gatekeeper function in the luminal membrane, which has been suggested for ABCB1 (P-glycoprotein), or efflux enhancement by transporters that pick up molecules on one side of the luminal or abluminal membrane and release them on the other side. Pharmacokinetic models including passive transport, influx hindrance, and efflux enhancement were built using the computer program MATLAB. The simulations were based on experimentally obtained parameters for morphine, morphine-3-glucuronide, morphine-6-glucuronide, and gabapentin.
RESULTS: The influx hindrance process is the more effective for keeping brain concentrations low. Efflux enhancement decreases the half-life of the drug in the brain, whereas with influx hindrance the half-life is similar to that seen with passive transport. The relationship between the influx and efflux of the drug across the blood-brain barrier determines the steady-state ratio of brain to plasma concentrations of unbound drug, K(p,uu).
CONCLUSIONS: Both poorly and highly permeable drugs can reach the same steady-state ratio, although the time to reach steady state will differ. The volume of distribution of unbound drug in the brain does not influence K(p,uu), but does influence the total brain-to-blood ratio K(p) and the time to reach steady state in the brain.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16575498     DOI: 10.1007/s11095-006-9780-0

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  36 in total

1.  Blood-brain barrier transport and brain distribution of morphine-6-glucuronide in relation to the antinociceptive effect in rats--pharmacokinetic/pharmacodynamic modelling.

Authors:  M R Bouw; R Xie; K Tunblad; M Hammarlund-Udenaes
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

Review 2.  The ATP switch model for ABC transporters.

Authors:  Christopher F Higgins; Kenneth J Linton
Journal:  Nat Struct Mol Biol       Date:  2004-10       Impact factor: 15.369

3.  The simultaneous estimation of the influx and efflux blood-brain barrier permeabilities of gabapentin using a microdialysis-pharmacokinetic approach.

Authors:  Y Wang; D F Welty
Journal:  Pharm Res       Date:  1996-03       Impact factor: 4.200

4.  Rationale for influx enhancement versus efflux blockade to increase drug exposure to the brain.

Authors:  P L Golden; G M Pollack
Journal:  Biopharm Drug Dispos       Date:  1998-05       Impact factor: 1.627

Review 5.  Kinetics of the multidrug transporter (P-glycoprotein) and its reversal.

Authors:  W D Stein
Journal:  Physiol Rev       Date:  1997-04       Impact factor: 37.312

6.  Estimates of Michaelis-Menten constants for the two membranes of the brain endothelium.

Authors:  A Gjedde; O Christensen
Journal:  J Cereb Blood Flow Metab       Date:  1984-06       Impact factor: 6.200

7.  Cerebral glucose transport and oxygen consumption in sheep and rabbits.

Authors:  J R Pappenheimer; B P Setchell
Journal:  J Physiol       Date:  1973-09       Impact factor: 5.182

8.  Kinetic analysis of the mechanism of action of the multidrug transporter.

Authors:  H Ashida; T Oonishi; N Uyesaka
Journal:  J Theor Biol       Date:  1998-11-21       Impact factor: 2.691

9.  Comparison of in vitro and in vivo models of drug transcytosis through the blood-brain barrier.

Authors:  W M Pardridge; D Triguero; J Yang; P A Cancilla
Journal:  J Pharmacol Exp Ther       Date:  1990-05       Impact factor: 4.030

10.  Efflux transport of tolbutamide across the blood-brain barrier.

Authors:  H Takanaga; H Murakami; N Koyabu; H Matsuo; M Naito; T Tsuruo; Y Sawada
Journal:  J Pharm Pharmacol       Date:  1998-09       Impact factor: 3.765

View more
  17 in total

Review 1.  Challenges of using in vitro data for modeling P-glycoprotein efflux in the blood-brain barrier.

Authors:  Noora Sjöstedt; Hanna Kortejärvi; Heidi Kidron; Kati-Sisko Vellonen; Arto Urtti; Marjo Yliperttula
Journal:  Pharm Res       Date:  2014-01       Impact factor: 4.200

2.  P-glycoprotein deficient mouse in situ blood-brain barrier permeability and its prediction using an in combo PAMPA model.

Authors:  Claude Dagenais; Alex Avdeef; Oksana Tsinman; Adam Dudley; Richard Beliveau
Journal:  Eur J Pharm Sci       Date:  2009-07-08       Impact factor: 4.384

Review 3.  Advances in PET imaging of P-glycoprotein function at the blood-brain barrier.

Authors:  Stina Syvänen; Jonas Eriksson
Journal:  ACS Chem Neurosci       Date:  2012-12-04       Impact factor: 4.418

4.  Synthesis and small-animal positron emission tomography evaluation of [11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrier.

Authors:  Bernd Dörner; Claudia Kuntner; Jens P Bankstahl; Marion Bankstahl; Johann Stanek; Thomas Wanek; Gloria Stundner; Severin Mairinger; Wolfgang Löscher; Markus Müller; Oliver Langer; Thomas Erker
Journal:  J Med Chem       Date:  2009-10-08       Impact factor: 7.446

5.  Age dependency of cerebral P-gp function measured with (R)-[11C]verapamil and PET.

Authors:  Martin Bauer; Rudolf Karch; Friederike Neumann; Aiman Abrahim; Claudia C Wagner; Kurt Kletter; Markus Müller; Markus Zeitlinger; Oliver Langer
Journal:  Eur J Clin Pharmacol       Date:  2009-08-05       Impact factor: 2.953

6.  Effects of hepatic ischemia-reperfusion injury on the P-glycoprotein activity at the liver canalicular membrane and blood-brain barrier determined by in vivo administration of rhodamine 123 in rats.

Authors:  Mohammad K Miah; Imam H Shaik; Ulrich Bickel; Reza Mehvar
Journal:  Pharm Res       Date:  2013-09-25       Impact factor: 4.200

7.  Peripheral and central H1 histamine receptor occupancy by levocetirizine, a non-sedating antihistamine; a time course study in the guinea pig.

Authors:  A Gupta; M Gillard; B Christophe; P Chatelain; R Massingham; M Hammarlund-Udenaes
Journal:  Br J Pharmacol       Date:  2007-06-11       Impact factor: 8.739

8.  Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET.

Authors:  Jens P Bankstahl; Claudia Kuntner; Aiman Abrahim; Rudolf Karch; Johann Stanek; Thomas Wanek; Wolfgang Wadsak; Kurt Kletter; Markus Müller; Wolfgang Löscher; Oliver Langer
Journal:  J Nucl Med       Date:  2008-07-16       Impact factor: 10.057

9.  Blood-brain and retinal barriers show dissimilar ABC transporter impacts and concealed effect of P-glycoprotein on a novel verapamil influx carrier.

Authors:  Hélène Chapy; Bruno Saubaméa; Nicolas Tournier; Fanchon Bourasset; Francine Behar-Cohen; Xavier Declèves; Jean-Michel Scherrmann; Salvatore Cisternino
Journal:  Br J Pharmacol       Date:  2016-01-15       Impact factor: 8.739

Review 10.  On the rate and extent of drug delivery to the brain.

Authors:  Margareta Hammarlund-Udenaes; Markus Fridén; Stina Syvänen; Anubha Gupta
Journal:  Pharm Res       Date:  2007-12-05       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.